Table 2.

Annual SGLT2 inhibitor and GLP1 receptor agonist use in the integrated health system clinics (2013–2019), overall and in high-risk patients.

Variable	2013	2014	2015	2016	2017	2018	2019	Absolute difference 2013–2019	95% confidence interval	p Value for trend
Integrated health system patients, total population
Eligible patients (n)	4522	4747	4915	5103	5496	6342	16422	–	–	–
Medication users (n)
SGLT2i	40	270	547	631	801	987	2405	–	–	P < 0.01
GLP1-RA	471	578	682	679	722	940	1671	–	–	P = 0.99
Total	495	742	1059	1135	1302	1639	3539	–	–	P < 0.01
Prescription Rate (%)
SGLT2i	1%	6%	11%	12%	15%	16%	15%	14%	13%–15%	–
GLP1-RA	10%	12%	14%	13%	13%	15%	10%	0%	−1%–1%	–
Total	11%	16%	22%	22%	24%	26%	22%	11%	10%–12%	–
High-risk patient subgroup *
Eligible patients (n)	335	398	489	626	737	812	1395	–	–	–
Medication users (n)
SGLT2i	4	12	37	76	107	140	249	–	–	P < 0.01
GLP1-RA	21	30	49	52	73	96	142	–	–	P = 0.01
Total	24	38	77	114	158	203	340	–	–	P < 0.01
Prescription Rate (%)
SGLT2i	1%	3%	8%	12%	15%	17%	18%	17%	13%–21%	–
GLP1-RA	6%	8%	10%	8%	10%	12%	10%	4%	1%–7%	–
Total	7%	10%	16%	18%	21%	25%	24%	17%	12%–22%	–

Usage rates equal the number of medication users divided by the total eligible per year.

^*This includes patients with diabetes, an A1c >7.0%, an ICD-9 or ICD-10 diagnosis of HF or atherosclerotic CVD and with an active prescription for metformin.